|
Statland, Jeffrey M; Tawil, Rabi (2014) Risk of functional impairment in Facioscapulohumeral muscular dystrophy. Muscle Nerve 49:520-7
|
|
Hilbert, James E; Ashizawa, Tetsuo; Day, John W et al. (2013) Diagnostic odyssey of patients with myotonic dystrophy. J Neurol 260:2497-504
|
|
Kalman, Lisa; Tarleton, Jack; Hitch, Monica et al. (2013) Development of a genomic DNA reference material panel for myotonic dystrophy type 1 (DM1) genetic testing. J Mol Diagn 15:518-25
|
|
Hilbert, James E; Kissel, John T; Luebbe, Elizabeth A et al. (2012) If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials 33:302-11
|
|
Logigian, E L; Martens, W B; Moxley 4th, R T et al. (2010) Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 74:1441-8
|
|
Miller, R G; Jackson, C E; Kasarskis, E J et al. (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Neurology 73:1227-33
|
|
Miller, R G; Jackson, C E; Kasarskis, E J et al. (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1218-26
|
|
Meola, Giovanni; Moxley 3rd, Richard T (2004) Myotonic dystrophy type 2 and related myotonic disorders. J Neurol 251:1173-82
|
